SCHEMBL25829161

SCHEMBL25829161

CCC(=O)Nc1ccc(COC(=O)NC)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.59
RAB9A P51151 4/20 0.59
GAA P10253 3/20 0.59
MAPK1 P28482 1/20 0.53
MAPT P10636 3/20 0.49
ATM Q13315 1/20 0.49
MEN1 O00255 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
NAMPT P43490 1/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 2/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22154236 0.86 LTA4H (0.55) KMT2ARAB9AGAAMAPTMEN1
SCHEMBL23798353 0.86 KMT2A (0.58) KMT2ARAB9AGAAMAPK1MAPT
SCHEMBL19513381 0.84 MEN1 (0.58) KMT2ARAB9AMAPK1MAPTMEN1
SCHEMBL19075835 0.84 KMT2A (0.62) KMT2ARAB9AGAAMAPK1MAPT
SCHEMBL13411053 0.83 SMN1; SMN2 (0.56) KMT2ARAB9AMAPTATMMEN1
SCHEMBL21151887 0.82 TOP2A (0.47) KMT2ARAB9AGAAMAPTMEN1
SCHEMBL15702041 0.82 KMT2A (0.46) KMT2ARAB9AGAAMAPK1MEN1
SCHEMBL20160133 0.82 TOP2A (0.49) KMT2ARAB9AMAPTMEN1SMN1; SMN2
SCHEMBL19491615 0.81 RAB9A (0.59) KMT2ARAB9AGAAMAPK1MAPT
SCHEMBL26445737 0.81 MAPT (0.47) KMT2ARAB9AGAAMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701427-B2 Diels-alder conjugation methods REGENERON PHARMACEUTICALS, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701427-B2 Diels-alder conjugation methods GLUL, TGM2, GLS KMT2A 1013/4885RAB9A 3607/4885GAA 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.